Virus News and Research

Latest Virus News and Research

Global initiative to prevent HIV in babies

World leaders met to decide on the launch of a global plan with the goal of ensuring that every baby is born HIV-free by 2015 and that their mothers with the HIV virus live to raise them.

9 Jun 2011

Ilex, Cerus partner to distribute INTERCEPT Blood System in Israel and South Africa

Cerus Corporation today announced today that it has entered into agreements with Ilex Biotech Limited to distribute Cerus' INTERCEPT Blood System for platelets and plasma in South Africa and Israel.

9 Jun 2011

Adults with herpes zoster may face higher risk of multiple sclerosis

Taiwanese investigators have found that there can be a significantly higher risk of multiple sclerosis (MS) occurring in the year following a shingles, or herpes zoster, attack.

9 Jun 2011

Adjuvant combination generates memory CD8 T cells which could kill infected cells

Researchers at National Jewish Health have discovered how to prime a second arm of the immune system to potentially boost influenza vaccine effectiveness. A combination of two adjuvants, chemicals used to boost the effectiveness of some vaccines, induced CD8, or killer, T cells to join antibodies in response to influenza infection.

9 Jun 2011

Neurologix reports new results from NLX-P101 Phase 2 trial against Parkinson's disease

Neurologix, Inc. announced today several new results from the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease (PD) as part of a comprehensive presentation of study findings to the National Institutes of Health (NIH) Recombinant DNA Advisory Committee.

9 Jun 2011

Rockefeller, Scripps Research develop first genetically humanized mouse model for hepatitis C

Scientists at Rockefeller University and The Scripps Research Institute have developed the first genetically humanized mouse model for hepatitis C, an achievement that will enable researchers to test molecules that block entry of the hepatitis C virus into cells as well as potential vaccine candidates. The finding is reported in the June 9 issue of the journal Nature.

9 Jun 2011

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Hepatitis C virus (HCV)-associated liver disease continues to be the most common indication for liver transplantation (LT) in the United States accounting for nearly 50% of all liver transplants. Recurrence is universal in patients viremic at the time of transplantation with histological hepatitis developing in the majority of patients. Although the natural history of recurrent HCV is difficult to predict, it is widely accepted that cirrhosis from recurrent HCV occurs in up to 30% of patients within five years of transplantation.

8 Jun 2011

IAS calls on leaders to ensure inclusion of HIV cure research into international AIDS agenda

As world leaders meet this week to review progress and chart the future course of the global AIDS response at the 2011 UN General Assembly High-Level Meeting on AIDS in New York, the International AIDS Society (IAS) calls on leaders to ensure the inclusion of HIV cure research and its global strategy into the international HIV agenda and in all discussions, political decisions and funding strategies.

8 Jun 2011

GSK, Crucell to test second-generation malaria vaccine

GlaxoSmithKline and drug company Crucell, a division of Johnson & Johnson, will collaborate with the PATH Malaria Vaccine Initiative to test a second-generation malaria vaccine "within the next couple of months," Reuters reports.

8 Jun 2011

Pharmasset expands PSI-7977 clinical trial for treatment of chronic hepatitis C

Pharmasset, Inc. announced today the addition of three treatment cohorts to the ELECTRON trial of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV).

8 Jun 2011

Vaccine candidate produces immune response to antigen in all strains of influenza A

A universal influenza vaccine targeting a protein common to all strains of influenza A has safely produced an immune response in humans. If proven effective, the vaccine could eliminate the practice of creating a new flu vaccine annually to match predicted strains, with major implications for global health.

8 Jun 2011

MicroDose completes atropine inhaler Phase I study on nerve agent poisoning

MicroDose Therapeutx Inc. today announced that its collaborators at the University of Pittsburgh (Pitt) have completed a Phase I study at the University of Pittsburgh Medical Center with atropine sulfate delivered from the MicroDose proprietary dry powder inhaler (DPI).

8 Jun 2011

Hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment

Advanced hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

8 Jun 2011

NanoViricides' anti-influenza drug development studies to be presented at TechConnect World 2011

NanoViricides, Inc. announced today that it has been invited to present its anti-influenza drug development studies at the TechConnect World 2011 Conferences and Expo.

7 Jun 2011

Pennsylvania reports first detection of West Nile encephalitis in Greene County

Pennsylvania has reported its earliest detection of a West Nile virus-carrying mosquito since testing began in 2000, the Department of Environmental Protection said today. The first detection of 2011 was a mosquito collection in Morgan Township, Greene County, on May 17.

7 Jun 2011

Crucell, GSK and PATH MVI partner to develop second-generation vaccine against malaria

The PATH Malaria Vaccine Initiative (MVI) announced today that it has entered into a collaboration with Dutch biopharmaceutical company Crucell N.V. and GlaxoSmithKline.

7 Jun 2011

PATH malaria vaccine initiative to collaborate with GSK and Crucell in development of 2nd-generation malaria vaccine

The PATH Malaria Vaccine Initiative (MVI) announced today that it has entered into a collaboration with Dutch biopharmaceutical company Crucell N.V. and GlaxoSmithKline (GSK). This collaboration is aimed at developing a second-generation vaccine against malaria—a deadly disease that kills close to 800,000 people annually, most of them young children under age five in Africa. MVI drives the development of malaria vaccines by joining its scientific, managerial, and field expertise with companies, universities, and governments to test potential malaria vaccines and invest in those with the most promise.

6 Jun 2011

Commentary on 30th anniversary of AIDS

"Thirty years into the AIDS epidemic, we are faced with a choice. Are we content to tinker at the fringes of the epidemic, spending untold billions to treat a fraction of those in need for decades into the future? Or can we summon the political will to effectively deploy the prevention interventions that are already available to us and to make the necessary investments in research that could end this epidemic in our lifetime?"

6 Jun 2011

An anniversary — AIDS turns 30

Three decades after the first cases of AIDS were recorded, more than 60 million people have been infected worldwide. Scientists agree that the epidemic is far from over and, even with major treatment advances and improvement in understanding the illness, hurdles remain in the effort to eradicate the disease.

6 Jun 2011

New blog aims to help dispel many myths behind cervical smear test

In the UK, 20 per cent of women still do not attend smear tests, putting themselves at risk of leaving pre-cancerous cervical cells undetected. A new blog, entitled, 'my diary from down under', aims to help dispel many of the myths surrounding having a smear with the aim of putting women at ease and encouraging more women to attend their cervical screens when invited.

6 Jun 2011

Virus News and Research

Latest Virus News and Research

Global initiative to prevent HIV in babies

Ilex, Cerus partner to distribute INTERCEPT Blood System in Israel and South Africa

Adults with herpes zoster may face higher risk of multiple sclerosis

Adjuvant combination generates memory CD8 T cells which could kill infected cells

Neurologix reports new results from NLX-P101 Phase 2 trial against Parkinson's disease

Rockefeller, Scripps Research develop first genetically humanized mouse model for hepatitis C

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

IAS calls on leaders to ensure inclusion of HIV cure research into international AIDS agenda

GSK, Crucell to test second-generation malaria vaccine

Pharmasset expands PSI-7977 clinical trial for treatment of chronic hepatitis C

Vaccine candidate produces immune response to antigen in all strains of influenza A

MicroDose completes atropine inhaler Phase I study on nerve agent poisoning

Hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment

NanoViricides' anti-influenza drug development studies to be presented at TechConnect World 2011

Pennsylvania reports first detection of West Nile encephalitis in Greene County

Crucell, GSK and PATH MVI partner to develop second-generation vaccine against malaria

PATH malaria vaccine initiative to collaborate with GSK and Crucell in development of 2nd-generation malaria vaccine

Commentary on 30th anniversary of AIDS

An anniversary — AIDS turns 30

New blog aims to help dispel many myths behind cervical smear test

A new way of characterising biomolecules eBook

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Newsletters you may be interested in